FDA clears first AI tool that can diagnose sepsis

Prenosis, a health tech company, announced its FDA-approved AI-driven diagnostic tool for sepsis, marking a significant milestone in the field. Sepsis, a life-threatening response to infection, claims numerous lives annually, highlighting the critical need for early detection. Prenosis' innovation, the Sepsis ImmunoScore, leverages AI to analyse 22 parameters simultaneously, streamlining assessment and generating risk scores. Built on the Immunix platform, backed by a vast dataset, the tool seamlessly integrates into electronic health records, facilitating easy access and utilisation for clinicians. Its approval through the FDA's De Novo pathway underscores its uniqueness and potential impact.

While Prenosis leads in FDA approval for sepsis AI tools, similar solutions have emerged, such as Johns Hopkins University's system, demonstrating promising results in early detection. Epic Systems also ventured into AI-powered sepsis prediction, although its model faced criticism, prompting revisions to enhance performance. Prenosis, emphasising safety and efficacy, collaborated with regulators for approval, aligning with the FDA's updated guidance on software analysing life-threatening conditions. With approval secured, Prenosis aims to validate its tool's accuracy and expand its availability to hospitals globally, marking a significant advancement in sepsis management.

Click here to read the original news story.